NCT03741127Active, not recruitingPhase 1
Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
Open Label, Multicenter, Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
Source: ClinicalTrials.gov · Last updated 4 Mar 2026
Brief summary (registry, in English)
Subjects are enrolled in this study following completion or early discontinuation from a Poseida sponsored or supported study of P-BCMA-101 T cells and will be followed for a total of 15 years post treatment from the last P-BCMA-101 treatment. Subjects will be monitored for safety and efficacy to assess the risk of delayed adverse events (AEs) and assess long-term efficacy, and PK and quantification of P-BCMA-101 T cells. Rimiducid may be administered as indicated.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 7 Nov 2018
- Start date
- 29 Oct 2018
- Primary completion date
- Aug 2032
- Lead sponsor
- Poseida Therapeutics, Inc.
- Diseases
- Multiple myeloma
- NCT number
- NCT03741127
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 100
- From 29 Oct 2018 to the primary completion date, Aug 2032
- 13 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- Subjects who have received P-BCMA-101 and completed or discontinued early from a Poseida sponsored treatment protocol.
- Subject has provided informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (13)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Johns Hopkins University Coordinator of this site? Confirm its status | Baltimore | United States | Unknown status |
| University of Maryland Greenebaum Comprehensive Cancer Center Coordinator of this site? Confirm its status | Baltimore | United States | Unknown status |
| University of Chicago Coordinator of this site? Confirm its status | Chicago | United States | Unknown status |
| University of California, Davis Coordinator of this site? Confirm its status | Davis | United States | Unknown status |
| Colorado Blood Cancer Institute Coordinator of this site? Confirm its status | Denver | United States | Unknown status |
| Wayne State - Karmanos Cancer Institute Coordinator of this site? Confirm its status | Detroit | United States | Unknown status |
| MD Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
| Sarah Cannon Research Institute at Tennessee Oncology Coordinator of this site? Confirm its status | Nashville | United States | Unknown status |
| Vanderbilt University Medical Center Coordinator of this site? Confirm its status | Nashville | United States | Unknown status |
| University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
| University of California San Diego Coordinator of this site? Confirm its status | San Diego | United States | Unknown status |
| University of California San Francisco Coordinator of this site? Confirm its status | San Francisco | United States | Unknown status |
| University of Kansas Cancer Center Coordinator of this site? Confirm its status | Westwood | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.